Why does my GP want to reduce my opioid dose if it's helping my pain?

The evidence base for long-term opioids in chronic non-cancer pain has shifted significantly. The SPACE trial (Krebs, JAMA 2018) found that opioids were not superior to non-opioid therapies for back, hip, or knee pain at 12 months. Long-term opioids carry significant risks — tolerance (needing higher doses for the same effect), opioid-induced hyperalgesia (where prolonged use can paradoxically worsen pain sensitivity), constipation, hormonal effects, cognitive effects, falls, and overdose risk. A careful dose reduction, combined with alternative pain strategies, often maintains function while reducing these harms — though nothing happens without your agreement.

How slow does the dose reduction have to be?

Current guidelines recommend 5–10% of the total daily dose per week, or 10–25% per month — whichever is more comfortable. The pace is individualised: longer-term use generally warrants slower reduction. Some people prefer faster reductions and tolerate them well; others need extremely slow tapers over months to years. The taper can always be paused or reversed if withdrawal symptoms, significant pain flare, or distress occur. There is no fixed endpoint — a reduction from a high dose to a lower sustainable dose is a successful outcome, even if not complete cessation.

What happens if I try to stop opioids too quickly?

Rapid reduction or abrupt stopping can trigger an opioid withdrawal syndrome: sweating, goosebumps (piloerection), rapid heartbeat, elevated blood pressure, severe muscle aches and cramps, nausea, vomiting, diarrhoea, anxiety, insomnia, and intense cravings. Symptoms typically peak within 36–72 hours for short-acting opioids and later for methadone. The withdrawal is distressing but not life-threatening in otherwise healthy adults. However, forced rapid discontinuation is also associated with increased risk of relapse to illicit opioids and overdose death, which is why guidelines specifically prohibit prescribers from imposing abrupt stops.

What is naloxone and why have I been given it?

Naloxone rapidly reverses opioid overdose by blocking opioid receptors — it works within minutes and can save a life while waiting for an ambulance. Anyone on regular opioids is at some overdose risk, particularly if the dose is high, combined with other sedatives or alcohol, or if the opioid is being stopped and then restarted. The Australian federal government has funded free naloxone through the Take Home Naloxone program since July 2022. It is available from participating pharmacies without a prescription for patients or their family and carers. Your GP providing it is a standard safety measure, not a judgment about your use.

How do I manage pain while reducing opioids?

Reducing opioids works best alongside adding alternative pain strategies. These include regular paracetamol, topical agents (lidocaine or capsaicin patches), nerve pain medications such as duloxetine or pregabalin where appropriate, supervised physiotherapy and graded exercise, CBT-based pain management, and mindfulness programs. Your GP can refer you to a pain psychologist via a Mental Health Care Plan, to a physiotherapist or exercise physiologist via a GP Chronic Condition Management Plan, and to a pain specialist for more complex situations. These non-opioid approaches target the pain from different angles and often provide better long-term function.

Opioid weaning and tapering

Opioid tapering in AU general practice: shared, slow, and safe

By Dr HB Lo, FACRRM Reviewed 13 July 2026 11 min read

Opioid tapering is a structured, patient-centred reduction in long-term opioid therapy for chronic non-cancer pain — aiming to reduce dose, not necessarily to zero — to improve function and reduce harm.

Tapering must be shared and slow: typically 5–10% of total daily dose per week or 10–25% per month, paired with multimodal pain management and support. Never forcing a taper is a core safety principle — abrupt discontinuation is linked to increased suicide and overdose risk.

About 3.1 million Australians were dispensed an opioid in 2022–23. Real-time prescription monitoring is now mandatory state-by-state before prescribing any Schedule 8 opioid.

Approximately 3.1 million Australians were dispensed an opioid in 2022–23, and around 1,800 opioid-related deaths are recorded each year — exceeding road trauma fatalities — per the AIHW Opioid Harms in Australia 2024 report. Most of this harm involves pharmaceutical opioids prescribed for chronic non-cancer pain, not illicit heroin.

The evidence base for long-term opioid therapy in chronic non-cancer pain has fundamentally shifted. Current guidelines from the Faculty of Pain Medicine ANZCA, RACGP Prescribing Drugs of Dependence 2024, and the CDC 2022 Clinical Practice Guideline agree: for most chronic non-cancer pain conditions, carefully structured dose reduction or cessation, combined with multimodal alternatives, supports better function and lower harm than continued or escalating opioid therapy.

The single most important safety principle: never force a taper. Unilateral prescriber-imposed discontinuation is associated with increased suicide and overdose — this is not a theoretical risk but a documented finding from large cohort studies. Any dose reduction must be collaborative, paced to the patient, and reversible if significant distress occurs.

A. Core clinical — the AU general-practice framework

Assessment before tapering

A structured assessment creates the foundation for a safe, individualised taper plan.

Pain history:

Current pain location, character, severity, and functional impact
Underlying diagnosis and its trajectory
History of prior investigations and treatments
Patient’s goals — what would “better” look like functionally, not just numerically on a pain scale

Opioid history:

Current drug, dose, formulation (immediate-release versus extended-release), and frequency
Prescribing history — how long, dose escalations, any prior reduction attempts and their outcomes
Red flags: early refill requests, lost prescriptions, emergency department presentations for opioids, dose borrowed from family members
Calculate the morphine-equivalent daily dose (MEDD) — this allows standardised comparison across different opioids; doses >90 mg MEDD carry substantially higher overdose risk

Concomitant risk factors:

Benzodiazepine co-prescription — 3-fold increase in overdose risk (Park BMJ 2015)
Gabapentinoid co-prescription — 1.5-fold increase in opioid-related death (Gomes JAMA Intern Med 2017)
Alcohol use and other sedating substances
Prior overdose, including accidental

Mental health screen:

Depression (PHQ-9), anxiety (GAD-7), PTSD (PCL-5) — all amplify perceived pain and are common comorbidities in chronic opioid users
Suicidal ideation — assess and document; high-risk period includes during and shortly after dose reduction
Previous episodes of self-harm

Screen for opioid use disorder (OUD): OUD is a DSM-5 diagnosis requiring ≥2 of 11 criteria over 12 months, including loss of control, compulsive use despite harm, craving, and tolerance. Physical dependence (tolerance plus withdrawal on cessation) is expected with chronic opioid use and is not OUD. If OUD is present, the management pathway shifts to opioid agonist therapy (see Section C) rather than simple tapering.

Real-Time Prescription Monitoring (RTPM): Check the patient’s state RTPM system — SafeScript Victoria, QScript Queensland, SafeScript NSW, ScriptCheck SA and WA, DORA ACT/NT, Tasmania RTPM — before every Schedule 8 prescription. This is a legal requirement in most Australian states. RTPM identifies concurrent prescribers, dispensing patterns, and high-dose combinations.

Setting goals collaboratively

The goal of tapering is not necessarily zero opioid — it is improved function, reduced harm, and the lowest effective dose. Some patients achieve full cessation; others settle at a lower stable dose that maintains function with fewer side effects. A written taper plan, agreed by the patient, with clearly documented goals, is best practice per RACGP.

Use the PEG scale (Pain intensity, Enjoyment of life, General activity) at each visit to track functional outcomes, not just pain scores in isolation. Function is the meaningful measure.

B. The evidence for tapering — why and how

Opioids are not superior for chronic non-cancer pain

The SPACE trial (Krebs JAMA 2018) randomly assigned 240 patients with chronic back, hip, or knee pain to opioid therapy or non-opioid therapy over 12 months. Opioids were not superior to non-opioid treatment for pain-related function at any timepoint, while side effects were significantly higher in the opioid group. This was not a comparison between treatments — it was a head-to-head trial at 12 months in real-world settings, and opioids lost.

Dose reduction improves outcomes

Frank et al. (Ann Intern Med 2017) reviewed patient outcomes following dose reduction or discontinuation of long-term opioid therapy. Dose reduction was associated with improved pain severity and quality of life in most cases, with gradual collaborative tapering producing better outcomes than rapid discontinuation. This evidence base supports the GP having the conversation about tapering as genuinely in the patient’s interest.

Never force a taper — the overdose and suicide signal

Oliva et al. (BMJ 2020) examined outcomes following prescriber-initiated discontinuation of long-term opioid therapy and found a significantly elevated risk of suicide and overdose — including accidental overdose from illicitly obtained opioids — in the period following forced discontinuation. The CDC 2022 guideline update specifically retracted prior guidance that implied dose limits or discontinuation should be imposed without patient agreement, and prohibits forcing patients off opioids against their will.

C. Taper protocol and withdrawal management

The slow taper

Per Faculty of Pain Medicine ANZCA 2023 and RACGP 2024:

Rate: 5–10% of the total current daily dose per week, or 10–25% per month
Slower for longer-duration use (years); faster only if the patient prefers and tolerates it
Simplify first if multiple opioids are prescribed — rotate to a single agent
Reduce immediate-release doses before extended-release formulations or patches
Pause if significant withdrawal, distress, or functional decline occurs — return to the prior tolerated dose and resume more gradually after stabilisation
Reversing the taper is not failure — it is an appropriate clinical response to individual variation

Multimodal alternative pain management

Initiating alternatives simultaneously with the taper is essential — the taper works best when replacing the opioid with other active pain strategies rather than simply removing it.

Non-pharmacological: CBT for chronic pain (CBT-CP), Acceptance and Commitment Therapy (ACT), mindfulness-based stress reduction, physiotherapy and graded exercise, hydrotherapy
Non-opioid analgesics: Regular paracetamol; topical NSAIDs or lidocaine 5% patches where appropriate; duloxetine (NPS MedicineWise) for neuropathic pain or fibromyalgia; pregabalin or gabapentin for confirmed neuropathic pain (Authority Required Streamlined on PBS); low-dose tricyclic antidepressants (amitriptyline, nortriptyline) for neuropathic or sleep disruption
Note on gabapentinoid–opioid combination: When both are co-prescribed, the overdose risk increases substantially (Gomes JAMA Intern Med 2017). If both are needed, use the lowest possible doses and monitor closely. Reducing or ceasing the gabapentinoid separately may be a priority.

Withdrawal symptom management

Per AMH, targeted symptomatic relief reduces withdrawal severity and supports taper adherence:

Clonidine 50–150 mcg orally three times daily — autonomic symptoms (sweating, tachycardia, hypertension); monitor blood pressure closely; start at the low end
Loperamide 2–4 mg as needed — diarrhoea and abdominal cramping (avoid >16 mg/day due to QT risk)
Paracetamol plus ibuprofen — myalgia and non-specific pain (if eGFR permits short-course NSAIDs)
Ondansetron 4–8 mg three times daily — nausea and vomiting
Hydroxyzine 25 mg three times daily — anxiety and insomnia (less sedating than benzodiazepines)
Avoid prescribing benzodiazepines for opioid withdrawal in general practice — the combination significantly increases overdose risk

When opioid agonist therapy is the right pathway

If simple tapering fails or OUD is present, opioid agonist therapy (OAT) is the evidence-based alternative. Per RACGP 2024 and Faculty of Pain Medicine ANZCA 2023:

Buprenorphine-naloxone (Suboxone) — first-line OAT; requires prescriber accreditation (state-by-state via Drug and Alcohol services or completion of an accredited training programme); long-acting injectable formulations (Buvidal weekly/monthly, Sublocade monthly) are rapidly expanding in availability
Methadone — specialist alcohol and other drugs (AOD) service initiation; QTc monitoring and drug-interaction assessment required; dispensed daily at a pharmacy initially
Buprenorphine micro-induction — starting very low doses (0.25–0.5 mg sublingually) while continuing the existing full-mu opioid, then titrating over 7–10 days; avoids precipitated withdrawal; useful when standard induction is poorly tolerated

Naloxone provision for every patient on chronic opioids: Australia’s Take Home Naloxone program has funded free naloxone (Nyxoid intranasal spray 1.8 mg or Prenoxad IM) nationally since 1 July 2022. It is available without a prescription from participating community pharmacies for patients, family members, carers, or any person likely to witness an overdose. Prescribing it at every opioid prescription review is good general practice.

D. Australian operations

MBS items: GP consultations item 23, 36, 44 — opioid taper review is Level C or D work. GP Chronic Condition Management Plan (item 965 preparation, item 967 review) — chronic non-cancer pain qualifies; allied health access (physiotherapy, exercise physiology, dietitian — 5 visits/year aggregate). Mental Health Care Plan (item 2715 or item 2717) for comorbid depression, anxiety, PTSD, or adjustment disorder — up to 10 + 10 psychology sessions per calendar year under Better Access. Case conferencing (item 132 or item 133) for multidisciplinary pain and addiction input. Telehealth items 91790, 91891 — rural and regional opioid review benefits substantially from telehealth, noting Schedule 8 prescriptions may require in-person review per state regulations. MyMedicare voluntary registration supports continuity of care for complex chronic conditions including chronic pain.

PBS: Long-acting opioids for chronic non-cancer pain — PBS Authority Required (morphine, oxycodone, fentanyl patches, buprenorphine patches, hydromorphone). Buprenorphine-naloxone (Suboxone) — Authority Required for OUD via AOD-accredited prescriber. Long-acting injectable buprenorphine (Buvidal, Sublocade) — Authority Required; PBS-listed 2019–2022. Naloxone (Nyxoid, Prenoxad) — Authority Required for PBS subsidy; free under the Take Home Naloxone program at participating pharmacies without prescription. Clonidine — PBS general (off-label for opioid withdrawal). Pregabalin and gabapentin — PBS Authority Required Streamlined for refractory neuropathic pain. Duloxetine — PBS general for depression; Authority Required Streamlined for neuropathic pain.

RTPM is legally mandatory before every Schedule 8 opioid prescription in most Australian states: SafeScript Victoria (mandatory April 2020), QScript Queensland (2021), SafeScript NSW (2022), ScriptCheck SA and WA, DORA ACT, NT PRoDUR, Tasmania RTPM. Check before each script; document in the clinical notes.

State alcohol and other drugs (AOD) services: State-funded assessment, counselling, and OAT initiation; variable wait times. The Australasian Chapter of Addiction Medicine (AChAM, RACP) provides specialist referral pathways for complex OUD. Pain management specialists at Faculty of Pain Medicine ANZCA-affiliated centres offer interdisciplinary assessment.

E. Special populations

Pregnancy: Never abruptly stop opioids in pregnancy — rapid withdrawal risks placental abruption, foetal distress, and preterm labour. Opioid agonist therapy (buprenorphine or methadone) is the recommended approach, providing stable maternal opioid levels and reducing illicit drug exposure. Neonatal opioid withdrawal syndrome is an expected and manageable consequence, not a reason to avoid OAT. Joint obstetric and AOD specialist management is mandatory. Coordinate with a perinatal mental health service for comorbid depression and anxiety.

Older adults: Slower tapers are generally appropriate; start at 5% per month or even less. Falls risk on opioids is elevated and increases further during withdrawal (lightheadedness, postural hypotension from clonidine). Cognitive effects of opioids may mask or worsen dementia; withdrawal may temporarily worsen confusion. Comprehensive geriatric assessment before commencing taper identifies relevant frailty, polypharmacy, and cognitive factors. Buprenorphine patch formulations are more renally appropriate than morphine in the setting of reduced eGFR.

Cancer survivorship: Chronic pain in cancer survivors is not the same as active cancer pain. Opioids prescribed during active treatment may no longer be appropriate post-treatment. However, cancer survivors with permanent pain from surgery, radiation, or nerve injury deserve the same careful multimodal assessment and shared decision-making as any other chronic pain patient. Reflexive opioid continuation as a cancer-care legacy is worth reviewing at survivorship consultations.

Renal impairment: Rotate to buprenorphine (patch or sublingual) or fentanyl when eGFR declines below 30 — morphine’s active metabolites accumulate in renal impairment and significantly increase overdose risk. Consult AMH for dose adjustments by eGFR.

When to escalate

Urgent or same-day referral:

Overdose — call 000 immediately; administer naloxone if available
Acute suicidal ideation during or shortly after dose reduction — mental health crisis line Lifeline 13 11 14 or emergency department
Severe opioid withdrawal in pregnancy
Suspected opioid-related acute organ toxicity

Semi-urgent referral within 1–2 weeks:

Failed taper with escalating distress or pain — pain specialist or addiction medicine
Suspected OUD (compulsive use, loss of control) — AOD service and AChAM physician
High MEDD (>100 mg morphine-equivalent daily) — pain specialist input before tapering
Concurrent benzodiazepine prescription — consider supervised concurrent slow benzodiazepine taper; addiction medicine or GP with addiction training
Comorbid PTSD, severe depression, or eating disorder complicating the pain and opioid picture

What this article is and is not

This is general health information drawn from current Australian and international guidelines — Faculty of Pain Medicine ANZCA 2023, RACGP Prescribing Drugs of Dependence 2024, AIHW Opioid Harms 2024, Australian Medicines Handbook, and NPS MedicineWise. It is not personal medical advice and does not create a doctor–patient relationship. Opioid tapering is a complex, individualised process that should be undertaken collaboratively with your own GP, pain specialist, or AOD clinician.

If you are experiencing suicidal thoughts, call Lifeline 13 11 14 or Beyond Blue 1300 22 4636, or go to your nearest emergency department. If you suspect an opioid overdose, call 000 immediately and administer naloxone if available.

Australian patient resources: Painaustralia; Take Home Naloxone program; HealthDirect — Opioid medicines; Better Health Channel; Pain Management Network NSW.

Sources cited

Frequently asked questions

Why does my GP want to reduce my opioid dose if it's helping my pain?

The evidence base for long-term opioids in chronic non-cancer pain has shifted significantly. The SPACE trial (Krebs, JAMA 2018) found that opioids were not superior to non-opioid therapies for back, hip, or knee pain at 12 months. Long-term opioids carry significant risks — tolerance (needing higher doses for the same effect), opioid-induced hyperalgesia (where prolonged use can paradoxically worsen pain sensitivity), constipation, hormonal effects, cognitive effects, falls, and overdose risk. A careful dose reduction, combined with alternative pain strategies, often maintains function while reducing these harms — though nothing happens without your agreement.
How slow does the dose reduction have to be?

Current guidelines recommend 5–10% of the total daily dose per week, or 10–25% per month — whichever is more comfortable. The pace is individualised: longer-term use generally warrants slower reduction. Some people prefer faster reductions and tolerate them well; others need extremely slow tapers over months to years. The taper can always be paused or reversed if withdrawal symptoms, significant pain flare, or distress occur. There is no fixed endpoint — a reduction from a high dose to a lower sustainable dose is a successful outcome, even if not complete cessation.
What happens if I try to stop opioids too quickly?

Rapid reduction or abrupt stopping can trigger an opioid withdrawal syndrome: sweating, goosebumps (piloerection), rapid heartbeat, elevated blood pressure, severe muscle aches and cramps, nausea, vomiting, diarrhoea, anxiety, insomnia, and intense cravings. Symptoms typically peak within 36–72 hours for short-acting opioids and later for methadone. The withdrawal is distressing but not life-threatening in otherwise healthy adults. However, forced rapid discontinuation is also associated with increased risk of relapse to illicit opioids and overdose death, which is why guidelines specifically prohibit prescribers from imposing abrupt stops.
What is naloxone and why have I been given it?

Naloxone rapidly reverses opioid overdose by blocking opioid receptors — it works within minutes and can save a life while waiting for an ambulance. Anyone on regular opioids is at some overdose risk, particularly if the dose is high, combined with other sedatives or alcohol, or if the opioid is being stopped and then restarted. The Australian federal government has funded free naloxone through the Take Home Naloxone program since July 2022. It is available from participating pharmacies without a prescription for patients or their family and carers. Your GP providing it is a standard safety measure, not a judgment about your use.
How do I manage pain while reducing opioids?

Reducing opioids works best alongside adding alternative pain strategies. These include regular paracetamol, topical agents (lidocaine or capsaicin patches), nerve pain medications such as duloxetine or pregabalin where appropriate, supervised physiotherapy and graded exercise, CBT-based pain management, and mindfulness programs. Your GP can refer you to a pain psychologist via a Mental Health Care Plan, to a physiotherapist or exercise physiologist via a GP Chronic Condition Management Plan, and to a pain specialist for more complex situations. These non-opioid approaches target the pain from different angles and often provide better long-term function.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.